The complexity of hyponatremia as a clinical problem is likely caused by the opposite scenarios that accompany this electrolyte disorder regarding pathophysiology (depletional versus dilutional hyponatremia, high versus low vasopressin levels) and therapy (rapid correction to treat cerebral edema versus slow correction to prevent osmotic demyelination, fluid restriction versus fluid resuscitation). For a balanced differentiation between these opposites, an understanding of the pathophysiology of hyponatremia is required. Therefore, in this review an attempt is made to translate the physiology of water balance regulation to strategies that improve the clinical management of hyponatremia. A physiology-based approach to the patient with hyponatremia is presented, first addressing the possibility of acute hyponatremia, and then asking if and if so why vasopressin is secreted non-osmotically. Additional diagnostic recommendations are not to rely too heavily of the assessment of the extracellular fluid volume, to regard the syndrome of inappropriate antidiuresis as a diagnosis of exclusion, and to rationally investigate the pathophysiology of hyponatremia rather than to rely on isolated laboratory values with arbitrary cutoff values. The features of the major hyponatremic disorders are discussed, including diuretic-induced hyponatremia, adrenal and pituitary insufficiency, the syndrome of inappropriate antidiuresis, cerebral salt wasting, and exercise-associated hyponatremia. The treatment of hyponatremia is reviewed from simple saline solutions to the recently introduced vasopressin receptor antagonists, including their promises and limitations. Given the persistently high rates of hospital-acquired hyponatremia, the importance of improving the management of hyponatremia seems both necessary and achievable.

Keywords:
Hyponatremia, Vasopressin, Water balance regulation
1.
Hoorn EJ, Lindemans J, Zietse R: Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006;21:70–76.
2.
Adrogue HJ, Madias NE: Hyponatremia. N Engl J Med 2000;342:1581–1589.
3.
Adrogue HJ: Consequences of inadequate management of hyponatremia. Am J Nephrol 2005;25:240–249.
4.
Hoorn EJ, Halperin ML, Zietse R: Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM 2005;98:529–540.
5.
Bourque CW, Oliet SH: Osmoreceptors in the central nervous system. Annu Rev Physiol 1997;59:601–619.
6.
McKinley MJ, Denton DA, Oldfield BJ, De Oliveira LB, Mathai ML: Water intake and the neural correlates of the consciousness of thirst. Semin Nephrol 2006;26:249–257.
7.
Sharif Naeini R, Witty MF, Seguela P, Bourque CW: An N-terminal variant of Trpv1 channel is required for osmosensory transduction. Nat Neurosci 2006;9:93–98.
8.
Oliet SH, Bourque CW: Mechanosensitive channels transduce osmosensitivity in supraoptic neurons. Nature 1993;364:341–343.
9.
Burbach JP, Luckman SM, Murphy D, Gainer H: Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 2001;81:1197–1267.
10.
Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA: Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205–244.
11.
Bankir L: Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372–390.
12.
Umenishi F, Narikiyo T, Vandewalle A, Schrier RW: cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-independent pathway. Biochim Biophys Acta 2006;1758:1100–1105.
13.
Chou CL, Christensen BM, Frische S, Vorum H, Desai RA, Hoffert JD, et al: Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct. J Biol Chem 2004;279:49026–49035.
14.
Anderson RJ, Chung HM, Kluge R, Schrier RW: Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164–168.
15.
Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, et al: Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884–1890.
16.
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127–137.
17.
Ghorbel MT, Sharman G, Leroux M, Barrett T, Donovan DM, Becker KG, et al: Microarray analysis reveals interleukin-6 as a novel secretory product of the hypothalamo-neurohypophyseal system. J Biol Chem 2003;278:19280–19285.
18.
Kurotani R, Yasuda M, Oyama K, Egashira N, Sugaya M, Teramoto A, et al: Expression of interleukin-6, interleukin-6 receptor (gp80), and the receptor’s signal-transducing subunit (gp130) in human normal pituitary glands and pituitary adenomas. Mod Pathol 2001;14:791–797.
19.
Beukhof CM, Hoorn EJ, Lindemans J, Zietse R: Novel risk factors for hospital-acquired hyponatraemia: a matched case-control study. Clin Endocrinol (Oxf) 2007;66:367–372.
20.
Hoorn EJ, Hoffert JD, Knepper MA: Combined proteomics and pathways analysis of collecting duct reveals a protein regulatory network activated in vasopressin escape. J Am Soc Nephrol 2005;16:2852–2863.
21.
Ellison DH, Berl T: Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064–2072.
22.
Hsu YJ, Chiu JS, Lu KC, Chau T, Lin SH: Biochemical and etiological characteristics of acute hyponatremia in the emergency department. J Emerg Med 2005;29:369–374.
23.
Shafiee MA, Charest AF, Cheema-Dhadli S, Glick DN, Napolova O, Roozbeh J, et al: Defining conditions that lead to the retention of water: the importance of the arterial sodium concentration. Kidney Int 2005;67:613–621.
24.
Halperin ML, Kamel KS, Sterns R: Hyponatremia in marathon runners. N Engl J Med 2005;353:427–428.
25.
Janicic N, Verbalis JG: Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 2003;32:459–481, vii.
26.
Gagnon RF, Halperin ML: Possible mechanisms to explain the absence of hyperkalaemia in Addison’s disease. Nephrol Dial Transplant 2001;16:1280–1284.
27.
Smith JC, Siddique H, Corrall RJ: Misinterpretation of serum cortisol in a patient with hyponatraemia. BMJ 2004;328:215–216.
28.
Diederich S, Franzen NF, Bahr V, Oelkers W: Severe hyponatremia due to hypopituitarism with adrenal insufficiency: report on 28 cases. Eur J Endocrinol 2003;148:609–617.
29.
Decaux G, Musch W, Penninckx R, Soupart A: Low plasma bicarbonate level in hyponatremia related to adrenocorticotropin deficiency. J Clin Endocrinol Metab 2003;88:5255–5257.
30.
Warner MH, Holding S, Kilpatrick ES: The effect of newly diagnosed hypothyroidism on serum sodium concentrations: a retrospective study. Clin Endocrinol (Oxf) 2006;64:598–599.
31.
Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C: Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007;18:606–612.
32.
Rose BD, Post TW: Clinical Physiology of Acid-Base and Electrolyte Disorders, ed 5. New York, McGraw-Hill, 2001.
33.
Decaux G, Namias B, Gulbis B, Soupart A: Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol 1996;7:805–810.
34.
Maesaka JK, Miyawaki N, Palaia T, Fishbane S, Durham JH: Renal salt wasting without cerebral disease: diagnostic value of urate determinations in hyponatremia. Kidney Int 2007;71:822–826.
35.
Maesaka JK, Venkatesan J, Piccione JM, Decker R, Dreisbach AW: Abnormal urate transport in patients with intracranial disease. Am J Kidney Dis 1992;19:10–15.
36.
Chung HM, Kluge R, Schrier RW, Anderson RJ: Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med 1987;83:905–908.
37.
McGee S, Abernethy WB 3rd, Simel DL: The rational clinical examination. Is this patient hypovolemic? JAMA 1999;281:1022–1029.
38.
Reynolds RM, Padfield PL, Seckl JR: Disorders of sodium balance. BMJ 2006;332:702–705.
39.
Carlotti AP, Bohn D, Mallie JP, Halperin ML: Tonicity balance, and not electrolyte-free water calculations, more accurately guides therapy for acute changes in natremia. Intensive Care Med 2001;27:921–924.
40.
Turchin A, Seifter JL, Seely EW: Clinical problem-solving. Mind the gap. N Engl J Med 2003;349:1465–1469.
41.
Aw TC, Kiechle FL: Pseudohyponatremia. Am J Emerg Med 1985;3:236–239.
42.
Hillier TA, Abbott RD, Barrett EJ: Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999;106:399–403.
43.
Hamburger S, Koprivica B, Ellerbeck E, Covinsky JO: Thiazide-induced syndrome of inappropriate secretion of antidiuretic hormone. Time course of resolution. JAMA 1981;246:1235–1236.
44.
Sonnenblick M, Friedlander Y, Rosin AJ: Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993;103:601–606.
45.
Chow KM, Szeto CC, Wong TY, Leung CB, Li PK: Risk factors for thiazide-induced hyponatraemia. QJM 2003;96:911–917.
46.
Friedman E, Shadel M, Halkin H, Farfel Z: Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med 1989;110:24–30.
47.
Robertson GL: Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006;119(suppl 1):S36–S42.
48.
Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, et al: Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997;349:245–249.
49.
Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988;319:1065–1072.
50.
Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988;319:1127–1134.
51.
Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV: Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581–2587.
52.
Londono MC, Guevara M, Rimola A, Navasa M, Taura P, Mas A, et al: Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135–1143.
53.
Goldberg A, Hammerman H, Petcherski S, Nassar M, Zdorovyak A, Yalonetsky S, Kapeliovich M, et al: Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 2006;166:781–786.
54.
Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH: Prostaglandins in severe congestive heart failure. Relation to activation of the renin–angiotensin system and hyponatremia. N Engl J Med 1984;310:347–352.
55.
Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA: Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162:323–328.
56.
Hoorn EJ, Lindemans J, Zietse R: Acute and concomitant deterioration of hyponatremia and renal dysfunction associated with heart and liver failure. Clin Nephrol 2006;65:248–255.
57.
Noakes TD, Goodwin N, Rayner BL, Branken T, Taylor RK: Water intoxication: a possible complication during endurance exercise. Med Sci Sports Exerc 1985;17:370–375.
58.
Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt DA, Duncan CN, et al: Hyponatremia among runners in the Boston Marathon. N Engl J Med 2005;352:1550–1556.
59.
Noakes TD, Sharwood K, Speedy D, Hew T, Reid S, Dugas J, et al: Three independent biological mechanisms cause exercise-associated hyponatremia: evidence from 2,135 weighed competitive athletic performances. Proc Natl Acad Sci USA 2005;102:18550–18555.
60.
Knochel JP, Dotin LN, Hamburger RJ: Pathophysiology of intense physical conditioning in a hot climate. I. Mechanisms of potassium depletion. J Clin Invest 1972;51:242–255.
61.
Siegel AJ, Verbalis JG, Clement S, Mendelson JH, Mello NK, Adner M, et al: Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med 2007;120:461.e11–461.e17.
62.
Thaler SM, Teitelbaum I, Berl T: ‘Beer potomania’ in non-beer drinkers: effect of low dietary solute intake. Am J Kidney Dis 1998;31:1028–1031.
63.
Musch W, Xhaet O, Decaux G: Solute loss plays a major role in polydipsia-related hyponatraemia of both water drinkers and beer drinkers. QJM 2003;96:421–426.
64.
Lohr JW: Osmotic demyelination syndrome following correction of hyponatremia: association with hypokalemia. Am J Med 1994;96:408–413.
65.
Decaux G: Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006;119:S79–S82.
66.
Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G: Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71.e1–71.e8.
67.
Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH: Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(suppl 1):S1–S21.
68.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099–2112.
69.
Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332–1343.
70.
Liamis G, Kalogirou M, Saugos V, Elisaf M: Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant 2006;21:1564–1569.
71.
Hoorn EJ, Zietse R: Tolvaptan for hyponatremia. N Engl J Med 2007;356:961; author reply 962–963.
72.
Detmers FJ, de Groot BL, Muller EM, Hinton A, Konings IB, Sze M, et al: Quaternary ammonium compounds as water channel blockers. Specificity, potency, and site of action. J Biol Chem 2006;281:14207–14214.
73.
Moritz ML, Ayus JC: Hospital-acquired hyponatremia: why are there still deaths? Pediatrics 2004;113:1395–1396.
74.
Patel GP, Balk RA: Recognition and treatment of hyponatremia in acutely ill hospitalized patients. Clin Ther 2007;29:211–229.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.